AVR

2.06%

$19.00 anteris technologies ltd

Interesting reading especially the comment that the aortic...

First 4 Last

Share
Profile

Follow
bar

625 Posts.

95

22/04/24

10:30

Post #: 73452318
Share

Originally posted by Ski123: ↑

4.2. DurAVR THV System (Anteris Technologies)DurAVR™
THV is a novel first-in-class biomimetic balloon-expandable valve made to particularly address the challenges related to the THV durability and hemodynamic performance.
DurAVR valve is made from a single piece of tissue which has been designed and molded to mimic the anatomy and performance of a native human aortic valve. This is distinct to all the other commercially available THVs that consist of three separate leaflet tissues sewn onto a valve frame.

Detailed computational fluid modeling comparing the two leaflet designs has revealed that the single-piece leaflet design facilitates optimal laminar flow which results in the uniform distribution of the leaflet stress and hence minimizes leaflet strain and prolongs durability. This results in a more uniform distribution of leaflet stress, facilitating optimal laminar flow and minimizing leaflet strain.
Furthermore, this unique leaflet design offers a larger coaptation area and improved coaptation length, reducing the risk of leaflet pin-rolling. Notably, the DurAVR THV also utilizes the novel ADAPT tissue-engineered anti-calcification technology, employing DNA- and glutaraldehyde-free acellular bovine pericardial leaflet tissue.
This decreases the risk of leaflet calcification and structural valve deterioration (SVD), contributing to the enhanced durability and longevity of the DurAVR THV System.

Additionally, the unique leaflet design allows for a shorter stent height with a spacious open cell geometry, and the ComASUR™ delivery system provides controlled deployment, potentially increasing the likelihood of achieving commissural alignment and facilitating coronary access [15].

In the first-in-human, prospective, single-arm, single-center study designed to assess the safety and feasibility of the DurAVR THV in 20 patients, procedural success was 100%, with no device-related complications.
The DurAVR demonstrated superior hemodynamics, with an effective orifice area (EOA) of 2.36 cm and a mean gradient of 7.8 mm Hg.
These hemodynamic effects were sustained at the 1-year follow-up in the first 12 patients. Furthermore, the CMR testing in the five patients matched to healthy controls showed that DurAVR maintains laminar aortic flow [15].

Expand

Interesting reading especially the comment that the aortic bicuspid valve in humans is 1 to 2 percent of the population but constitutes 50% of TAVR insertions.DurAVR seems to be the leader in valve in valve I would like data on DurAVR if used on bicuspid valve patients. 98% of the population have 3 cusps in their AV ,2% have 2 cusps. Less efficient and prone to degrading and stenosis.

AVR Price at posting: $23.00 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 11 more messages in this thread...

First 4 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $19.00		Change -0.400(2.06%)		Mkt cap ! $365.2M

Open	High	Low	Value	Volume
$19.35	$19.35	$18.49	$184.4K	9.773K

Buyers (Bids)

No.	Vol.	Price($)
1	100	$18.84

Sellers (Offers)

Price($)	Vol.	No.
$19.40	99	1

View Market Depth

No.	Vol.	Price($)
1	1000	18.500
1	54	18.480
1	200	18.440
1	200	18.410
1	50	18.400

Price($)	Vol.	No.
19.400	99	1
19.600	1965	1
19.990	6000	1
20.000	750	1
20.200	125	1

Last trade - 15.06pm 24/05/2024 (20 minute delay)


Last $18.92		Change -0.400 ( 0.84 %)
Open	High	Low	Volume
$19.26	$19.27	$18.52	328
Last updated 15.06pm 24/05/2024 ?

AVR (ASX) Chart

Interesting reading especially the comment that the aortic...

Featured News

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

AIC Mines raises $57m to extend Eloise copper mine lifecycle

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

PlaySide to take gamers back to Westeros with new PC title

Althea on a high as it opens cannabis drinks in the US with Flora Growth

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

The Telstra twist - What the job cuts decision mean for investors?

Nimy seeks massive sulphide systems through surveying at WA prospects

Buyers (Bids)

Sellers (Offers)

Featured News

Interesting reading especially the comment that the aortic...

Featured News

Top Stories

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

AIC Mines raises $57m to extend Eloise copper mine lifecycle

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

PlaySide to take gamers back to Westeros with new PC title

Althea on a high as it opens cannabis drinks in the US with Flora Growth

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

The Telstra twist - What the job cuts decision mean for investors?

Nimy seeks massive sulphide systems through surveying at WA prospects

Buyers (Bids)

Sellers (Offers)

Featured News